telmisartan + rosuvastatin + ezetimibe

**Rozetel** is an oral fixed-dose combination tablet developed and marketed by **GC Biopharma** for concurrent management of **hypertension** and **dyslipidemia**. Public clinical-trial and company materials identify it specifically as a three-drug polypill containing **telmisartan**, **rosuvastatin**, and **ezetimibe**. Its therapeutic rationale is complementary cardiovascular risk reduction: telmisartan blocks the angiotensin II type 1 receptor to lower blood pressure, rosuvastatin inhibits HMG-CoA reductase to reduce hepatic cholesterol synthesis and upregulate LDL receptor activity, and ezetimibe inhibits intestinal cholesterol absorption via NPC1L1. The product has been studied in real-world post-PCI patients for blood pressure and LDL-cholesterol control and is positioned for patients needing simultaneous antihypertensive and lipid-lowering therapy.

Brand names

Rozetel

Other names

telmisartan + rosuvastatin + ezetimibe